Distinct and overlapping effector functions of expanded human CD4 +, cd8α + and CD4 -CD8α - invariant natural killer T cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  O'Reilly, Vincent ^a   Zeng, Shijuan G ^a,d   Bricard, Gabriel ^b,e   Atzberger, Ann ^a   Hogan, Andrew E ^c   Jackson, John ^a   Feighery, Conleth ^a   Porcelli, Steven A ^b   Doherty, Derek G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d AGENCY FOR SCIENCE   (Singapore)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA; MITOGENIC AGENT;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; ANIMAL; CELL MEMBRANE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; HELA CELL; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; SECRETION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HELA CELLS; HUMANS; MICE; MITOGENS; NATURAL KILLER T-CELLS; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 83155164561     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028648     Document Type: Article

References (61)

1. Bendelac A, Savage PB, Teyton L, (2007) The biology of NKT cells. Annu Rev Immunol 25: 297-336.
2. Brigl M, Brenner MB, (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22: 817-890.
3. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
4. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, et al. (2004) Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
5. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1997) CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
6. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. (1997) Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
7. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, et al. (2001) Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167: 3114-3122.
8. Exley M, Garcia J, Balk SP, Porcelli S, (1997) Requirements for CD1d recognition by human invariant Vα24+ CD4-CD8- T cells. J Exp Med 186: 109-120.
9. Gumperz JE, Miyake S, Yamamura T, Brenner MB, (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195: 625-636.
10. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, et al. (2008) Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 180: 5167-5171.
11. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Nagahira K, et al. (2009) Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 254: 81-84.
12. Jiang X, Kojo S, Harada M, Ohkohchi N, Taniguchi M, et al. (2007) Mechanism of NKT cell-mediated transplant tolerance. Am J Transplant 7: 1482-1490.
13. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, et al. (1999) The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189: 1121-1128.
14. Fujii S, Shimizu K, Hemmi H, Steinman RM, (2007) Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220: 183-198.
15. Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, et al. (2008) Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 38: 1012-1023.
16. Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, et al. (2003) CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 197: 1051-1057.
17. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, et al. (2008) NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A 105: 8339-8344.
18. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, et al. (2001) The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7: 1052-1056.
19. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, et al. (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202: 1279-1288.
20. Behar SM, Porcelli SA, (2007) CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol 314: 215-250.
21. Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, et al. (2003) NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 171: 1775-1779.
22. Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, et al. (2009) Enrichment of human CD4+ Vα24/Vβ11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 182: 5140-5151.
23. Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, et al. (2005) Peripheral blood IFN-γ-secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116: 87-93.
24. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, et al. (2001) Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 167: 4046-4050.
25. Berzins SP, Smyth MJ, Baxter AG, (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11: 131-142.
26. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, et al. (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517.
27. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, et al. (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12: 6079-6086.
28. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, et al. (2009) Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 100: 1092-1098.
29. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, et al. (2002) A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709.
30. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, et al. (2005) A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917.
31. Moreira-Teixeira L, Resende M, Coffre M, Devergne O, Herbeuval JP, et al. (2011) Proinflammatory Environment Dictates the IL-17-Producing Capacity of Human Invariant NKT Cells. J Immunol 186: 5758-5765.
32. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, et al. (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1: 515-520.
33. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE, (2000) Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 1: 521-525.
34. Osada T, Morse MA, Lyerly HK, Clay TM, (2005) Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol 17: 1143-1155.
35. Schmieg J, Yang G, Franck RW, Tsuji M, (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-Galactosylceramide. J Exp Med 198: 1631-1641.
36. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, et al. (2007) Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A 104: 10299-10304.
37. Miyamoto K, Miyake S, Yamamura T, (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
38. Oki S, Chiba A, Yamamura T, Miyake S, (2004) The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113: 1631-1640.
39. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, et al. (2002) Cutting edge: analysis of human Vα24+CD8+ NK T cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168: 3140-3144.
40. Ho LP, Urban BC, Jones L, Ogg GS, McMichael AJ, (2004) CD4-CD8αα subset of CD1d-restricted NKT cells controls T cell expansion. J Immunol 172: 7350-7358.
41. Seino K, Taniguchi M, (2005) Functionally distinct NKT cell subsets and subtypes. J Exp Med 202: 1623-1626.
42. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ, (2006) Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 80: 164-173.
43. Lin H, Nieda M, Rozenkov V, Nicol AJ, (2006) Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells. Exp Hematol 34: 289-295.
44. Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, et al. (2007) Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122: 1-14.
45. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, et al. (2002) Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110: 793-800.
46. Lee PT, Benlagha K, Teyton L, Bendelac A, (2002) Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 195: 637-641.
47. Kim CH, Butcher EC, Johnston B, (2002) Distinct subsets of human Vα24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol 23: 516-519.
48. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, et al. (2003) Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 15: 279-288.
49. Im JS, Kang TJ, Lee SB, Kim CH, Lee SH, et al. (2008) Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin Immunol 127: 214-224.
50. Chattopadhyay PK, Yu J, Roederer M, (2005) A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 11: 1113-1117.
51. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG, (2003) Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα281 TCR. J Immunol 170: 1430-1434.
52. Noelle RJ, Nowak EC, (2010) Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 10: 683-687.
53. Yoshimoto T, Min B, Sugimoto T, Hayashi N, Ishikawa Y, et al. (2003) Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med 197: 997-1005.
54. Jones TG, Hallgren J, Humbles A, Burwell T, Finkelman FD, et al. (2009) Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. J Immunol 183: 5251-5260.
55. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, et al. (2006) CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 354: 1117-1129.
56. Monteiro M, Almeida CF, Caridade M, Ribot JC, Duarte J, et al. (2010) Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-β. J Immunol 185: 2157-2163.
57. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, et al. (1998) α/β-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187: 1047-1056.
58. Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, et al. (2011) Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. Clin Immunol 140: 196-207.
59. Bricard G, Venkataswamy MM, Yu KO, Im JS, Ndonye RM, et al. (2010) α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One 5: e14374.
60. Lin H, Nieda M, Nicol AJ, (2004) Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 34: 2664-2671.
61. Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, et al. (2007) Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 179: 3452-3462.